(Q42827930)

8 November 2017

title

The tyrosine kinase Abl is required for Src-transforming activity in mouse fibroblasts and human breast cancer cells (English)

1 reference

8 November 2017

A Sirvent

1

1 reference

8 November 2017

A Boureux

2

1 reference

8 November 2017

V Simon

3

1 reference

8 November 2017

C Leroy

4

1 reference

8 November 2017

S Roche

5

1 reference

8 November 2017

language of work or name

English

0 references

publication date

28 May 2007

1 reference

8 November 2017

1 reference

8 November 2017

volume

26

1 reference

8 November 2017

issue

52

1 reference

8 November 2017

page(s)

7313-7323

1 reference

Activation of either ERK1/2 or ERK5 MAP kinase pathways can lead to disruption of the actin cytoskeleton

8 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210543

7 January 2021

Abl tyrosine kinase regulates a Rac/JNK and a Rac/Nox pathway for DNA synthesis and Myc expression induced by growth factors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210543

7 January 2021

The interplay between Src family kinases and receptor tyrosine kinases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210543

7 January 2021

Stat3 activation is required for cellular transformation by v-src

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210543

7 January 2021

Abl-kinase-sensitive levels of ERK5 and its intrinsic basal activity contribute to leukaemia cell survival

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210543

7 January 2021

Roles of the Rac1 and Rac3 GTPases in human tumor cell invasion

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210543

7 January 2021

Src tyrosine kinase as a chemotherapeutic target: is there a clinical case?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210543

7 January 2021

Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210543

7 January 2021

EphrinA1 inactivates integrin-mediated vascular smooth muscle cell spreading via the Rac/PAK pathway

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210543

7 January 2021

Polyoma virus middle T antigen and its role in identifying cancer-related molecules

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210543

7 January 2021

Newest findings on the oldest oncogene; how activated src does it

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210543

7 January 2021

The adaptor protein Tom1L1 is a negative regulator of Src mitogenic signaling induced by growth factors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210543

7 January 2021

c-Abl is an effector of Src for growth factor-induced c-myc expression and DNA synthesis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210543

7 January 2021

ERK5 activates NF-kappaB in leukemic T cells and is essential for their growth in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210543

7 January 2021

Regulation of the c-Abl and Bcr-Abl tyrosine kinases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210543

7 January 2021

c-Src and cooperating partners in human cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210543

7 January 2021

BMK1/ERK5 regulates serum-induced early gene expression through transcription factor MEF2C

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210543

7 January 2021

Selective regulation of c-jun gene expression by mitogen-activated protein kinases via the 12-o-tetradecanoylphorbol-13-acetate- responsive element and myocyte enhancer factor 2 binding sites.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210543

7 January 2021

Phosphorylation site-specific inhibition of platelet-derived growth factor beta-receptor autophosphorylation by the receptor blocking tyrphostin AG1296.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210543

7 January 2021

Tyrosine kinases as targets for cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210543

7 January 2021

Integrin regulation of c-Abl tyrosine kinase activity and cytoplasmic-nuclear transport

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210543

7 January 2021

The hunting of the Src

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210543

7 January 2021

Selective activation of the JNK signaling cascadeand c-Jun transcriptional activity by the small GTPases Rac and Cdc42Hs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210543

7 January 2021

Activation of cyclin D1 expression by the ERK5 cascade

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210543

7 January 2021

ShcA tyrosine phosphorylation sites can replace ShcA binding in signalling by middle T-antigen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210543

7 January 2021

The Abl family kinases: mechanisms of regulation and signaling

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210543

7 January 2021

A new link between the c-Abl tyrosine kinase and phosphoinositide signalling through PLC-gamma1

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210543

7 January 2021

c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210543

7 January 2021

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210543

7 January 2021

Rac1 function is required for Src-induced transformation. Evidence of a role for Tiam1 and Vav2 in Rac activation by Src.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210543

7 January 2021

Abl-dependent tyrosine phosphorylation of Sos-1 mediates growth-factor-induced Rac activation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210543

7 January 2021

Activation of Abl tyrosine kinases promotes invasion of aggressive breast cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210543

7 January 2021

Loss of c-abl facilitates anchorage-independent growth of p53- and RB- deficient primary mouse embryonic fibroblasts

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210543

7 January 2021

Two distinct phosphorylation pathways have additive effects on Abl family kinase activation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210543

7 January 2021

Requirement for Ras/Rac1-mediated p38 and c-Jun N-terminal kinase signaling in Stat3 transcriptional activity induced by the Src oncoprotein

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210543

7 January 2021

A role for the small GTPase Rac in polyomavirus middle-T antigen-mediated activation of the serum response element and in cell transformation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210543

7 January 2021

cAbl tyrosine kinase mediates reactive oxygen species- and caveolin-dependent AT1 receptor signaling in vascular smooth muscle: role in vascular hypertrophy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210543

7 January 2021

Two distinct pools of Src family tyrosine kinases regulate PDGF-induced DNA synthesis and actin dorsal ruffles

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210543

7 January 2021

P68 RNA helicase mediates PDGF-induced epithelial mesenchymal transition by displacing Axin from beta-catenin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210543

7 January 2021

A renaissance for SRC

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210543

7 January 2021

Requirement for Abl kinases in T cell receptor signaling

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210543

7 January 2021

Signaling pathways activated by oncogenic forms of Abl tyrosine kinase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210543

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1210543

1 reference

Dimensions Publication ID

8 November 2017

1002138714

0 references

1 reference